Argenx’s Long-term Safety Study on Efgartigimod for Children with gMG: Key Insights for Investors

Argenx ((ARGX)) announced an update on their ongoing clinical study.

Argenx is conducting a clinical study titled ‘A Long-term, Single-Arm, Open-label, Multicenter Trial to Evaluate Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis.’ The study aims to assess the long-term safety of two forms of efgartigimod, a treatment for generalized myasthenia gravis (gMG) in children, following previous studies ARGX-113-2006 and ARGX-113-2207. This research is significant as it addresses the safety of these treatments in a vulnerable population.

The interventions being tested are Efgartigimod IV, administered intravenously, and Efgartigimod PH20 SC, administered subcutaneously. Both are biological treatments designed to manage symptoms of gMG by modulating the immune system.

The study is interventional, with a single-group assignment and no masking, focusing on treatment as the primary purpose. This straightforward design allows researchers to directly observe the safety outcomes of the treatments over time.

The study began on August 18, 2022, and is currently enrolling participants by invitation. The most recent update was submitted on July 16, 2025. These dates are crucial as they indicate the study’s progress and ongoing status.

From a market perspective, the successful demonstration of long-term safety could positively influence Argenx’s stock performance and investor confidence, especially as the company leads in innovative treatments for rare diseases. This study’s progress is particularly relevant in the competitive landscape of autoimmune disorder treatments.

The study is ongoing, with further details available on the ClinicalTrials portal.